Expert opinion on investigational drugs最新文献_第3页

Odronextamab: a bispecific antibody for follicular lymphoma. odronexamab：滤泡性淋巴瘤的双特异性抗体。

IF 4.3 2区医学

Expert opinion on investigational drugs Pub Date : 2026-07-01 Epub Date: 2026-06-24 DOI: 10.1080/13543784.2026.2689652

Alejandro Martín García-Sancho, Almudena Cabero-Martínez, Norma C Gutiérrez

{"title":"Odronextamab: a bispecific antibody for follicular lymphoma.","authors":"Alejandro Martín García-Sancho, Almudena Cabero-Martínez, Norma C Gutiérrez","doi":"10.1080/13543784.2026.2689652","DOIUrl":"10.1080/13543784.2026.2689652","url":null,"abstract":"Introduction: Follicular lymphoma (FL) is an indolent lymphoma characterized by repeated relapses and progressively shorter responses with successive lines of therapy, particularly in patients with early progression (POD24). Although chemoimmunotherapy has historically dominated treatment, the therapeutic landscape has shifted toward chemo-free approaches. T-cell-redirecting therapies, including bispecific antibodies, have demonstrated high efficacy in relapsed/refractory (R/R) FL.Areas covered: This review discusses the role of odronextamab in FL, including its mechanism of action, pharmacokinetic properties, and key clinical efficacy and safety data from the ELM-1 and ELM-2 trials, which supported its approval by the European Medicines Agency (EMA). Future development strategies are also reviewed, including combinations with other agents and use in earlier lines of therapy, including the frontline setting, as investigated in the phase III OLYMPIA-1, OLYMPIA-2, and OLYMPIA-5 studies.Expert opinion: Odronextamab has shown highly promising single-agent activity in R/R FL. Although its efficacy and safety appear broadly comparable to those of mosunetuzumab and epcoritamab, differences in treatment duration, route of administration, dosing frequency, and cytokine release syndrome prophylaxis may influence treatment selection. Ongoing phase III studies may further define its role across the FL treatment continuum.","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"489-497"},"PeriodicalIF":4.3,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148239224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advancements in longevity pharmacology research - are we finally seeing clinical progression? 长寿药理学研究的进步——我们终于看到临床进展了吗？

IF 4.3 2区医学

Expert opinion on investigational drugs Pub Date : 2026-07-01 Epub Date: 2026-07-16 DOI: 10.1080/13543784.2026.2698526

Madia Lozupone

{"title":"Advancements in longevity pharmacology research - are we finally seeing clinical progression?","authors":"Madia Lozupone","doi":"10.1080/13543784.2026.2698526","DOIUrl":"10.1080/13543784.2026.2698526","url":null,"abstract":"Instruction: Longevity pharmacology has evolved from descriptive gerontology into a mechanistically driven field aiming to modulate fundamental processes of biological aging. Despite rapid scientific advances, whether this progress has translated into meaningful clinical outcomes remains uncertain.Areas covered: This critical perspective evaluates recent developments in longevity pharmacology and examines whether they represent genuine clinical progression or continued translational delay. A narrative literature review was conducted using PubMed/MEDLINE, Scopus, and Web of Science to identify English-language publications related to longevity pharmacology, gerotherapeutics, biomarkers of aging, and translational geroscience published between January 2000 and April 2026. We review evidence from senescence biology (including frailty), autophagy and mitophagy modulation, metabolic and nutrient-sensing pathways, stem cell and natural product - based rejuvenation strategies, microbiome-targeted interventions, and AI-enabled biomarker development. Particular emphasis is placed on systemic chronic inflammation as a central integrative driver of age-related disease. While selected interventions show early clinical signals, most remain preclinical or lack long-term validation. Key barriers include biomarker deficits, biological heterogeneity, safety concerns, regulatory misalignment, and limitations of animal models.Expert opinion: Although mechanistic maturity is advancing rapidly, clinical translation remains incremental and fragmented. Near-term progress is most likely to arise from low-risk, system-level interventions supported by validated biomarkers and geroscience-informed clinical trial designs.","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"503-517"},"PeriodicalIF":4.3,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148375122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cognitive-enhancing drugs in Phase II clinical trials for Alzheimer's disease: emerging therapeutic candidates. 阿尔茨海默病II期临床试验中的认知增强药物：新出现的治疗候选药物。

IF 4.3 2区医学

Expert opinion on investigational drugs Pub Date : 2026-07-01 Epub Date: 2026-08-03 DOI: 10.1080/13543784.2026.2710112

Patricia Regina Manzine, Marina Carrasco, Thaís Antonia Alves Fernandes, Suelen Santos Alves, Laura Guzman, Leila Driouech, Mireia Millet-Sigalat, Norberto Garcia Cairasco, Jordi Olloquequi, M Emilia Juan, Miren Ettcheto, Marcia Regina Cominetti, Antoni Camins

{"title":"Cognitive-enhancing drugs in Phase II clinical trials for Alzheimer's disease: emerging therapeutic candidates.","authors":"Patricia Regina Manzine, Marina Carrasco, Thaís Antonia Alves Fernandes, Suelen Santos Alves, Laura Guzman, Leila Driouech, Mireia Millet-Sigalat, Norberto Garcia Cairasco, Jordi Olloquequi, M Emilia Juan, Miren Ettcheto, Marcia Regina Cominetti, Antoni Camins","doi":"10.1080/13543784.2026.2710112","DOIUrl":"10.1080/13543784.2026.2710112","url":null,"abstract":"Introduction: Alzheimer's disease (AD) is biologically defined by amyloid-β (Aβ) and tau pathology but clinically manifests as progressive synaptic dysfunction and cognitive decline. Although anti-amyloid and anti-tau therapies modestly slow disease progression, they do not directly restore cognition or synaptic function.Areas covered: Phase II trials of cognition‑enhancing therapies in AD and prodromal AD were reviewed to identify factors behind success or failure. Trials from ClinicalTrials.gov and the EU Clinical Trials Register with cognitive endpoints were assessed by mechanism, design, population, and outcomes. Strategies included synaptic, inflammatory, metabolic, vascular, and regenerative approaches.Most therapies showed limited or inconsistent cognitive effects, and many trials did not demonstrate clear efficacy.Expert opinion: Phase II cognition‑enhancing trials in AD show biological plausibility but remain methodologically limited. Cognitive signal detection depends on the fit between mechanism, disease stage, and trial design, and on the statistical approach used to capture subtle change. Outcome variability highlights the need for sensitive cognitive measures and adequate power. Progress will require precision‑enriched designs, with biomarker‑defined populations, cognitive‑trajectory modeling, and integrated cognitive and functional endpoints.","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"607-641"},"PeriodicalIF":4.3,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148618934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Taxane therapy in mCRPC: current positioning and emerging strategies to overcome resistance. 紫杉烷治疗mCRPC：目前的定位和克服耐药性的新策略。

IF 4.3 2区医学

Expert opinion on investigational drugs Pub Date : 2026-07-01 Epub Date: 2026-08-20 DOI: 10.1080/13543784.2026.2713042

Ling Wang, Yanfeng Tang, Mingsheng Liu, Hongqing Zhou, Hao Zeng, Bo Tang

{"title":"Taxane therapy in mCRPC: current positioning and emerging strategies to overcome resistance.","authors":"Ling Wang, Yanfeng Tang, Mingsheng Liu, Hongqing Zhou, Hao Zeng, Bo Tang","doi":"10.1080/13543784.2026.2713042","DOIUrl":"10.1080/13543784.2026.2713042","url":null,"abstract":"Introduction: Metastatic castration-resistant prostate cancer (mCRPC) remains a major cause of prostate cancer-related mortality. Taxane-based chemotherapy, including docetaxel and cabazitaxel, remains an important treatment option despite the expanding use of androgen receptor signaling inhibitors (ARSIs), poly(ADP-ribose) polymerase (PARP) inhibitors, and prostate-specific membrane antigen (PSMA)-targeted radioligand therapy.Areas covered: A structured literature search was conducted in PubMed/MEDLINE, Web of Science, and ClinicalTrials.gov from inception to March 2026. This review summarizes the evolving clinical role of docetaxel and cabazitaxel in mCRPC and briefly outlines the biological mechanisms underlying taxane activity and resistance as a rationale for therapeutic development. Particular emphasis is placed on investigational strategies designed to delay or overcome taxane resistance, including AR pathway-directed combinations, platinum-taxane strategies, PI3K/AKT/mTOR- and other pathway-directed combinations, immunotherapy or radiopharmaceutical combinations, and preclinical resistance-directed approaches. Treatment sequencing, toxicity, quality of life, evidence maturity, and biomarker-informed patient selection are also discussed.Expert opinion: Taxane resistance is biologically heterogeneous and incompletely captured by current biomarkers. Cabazitaxel after prior docetaxel and early ARSI progression remains the most established sequencing strategy, whereas most resistance-directed approaches remain investigational. Future progress will depend on molecular and imaging-based selection, rational early-phase trial design, and mechanism-informed taxane combinations.","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"591-606"},"PeriodicalIF":4.3,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148790160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Peripheral cannabinoid-1 receptor antagonists in clinical development: therapeutic potential for the management of obesity and related metabolic disorders. 外周大麻素-1受体拮抗剂在临床开发：治疗肥胖和相关代谢紊乱管理的潜力。

IF 4.3 2区医学

Expert opinion on investigational drugs Pub Date : 2026-07-01 Epub Date: 2026-08-21 DOI: 10.1080/13543784.2026.2713043

Jonanne Talebloo, Esha Chawla, Donya Shahamati, Swas Shiv, Kishore M Gadde

{"title":"Peripheral cannabinoid-1 receptor antagonists in clinical development: therapeutic potential for the management of obesity and related metabolic disorders.","authors":"Jonanne Talebloo, Esha Chawla, Donya Shahamati, Swas Shiv, Kishore M Gadde","doi":"10.1080/13543784.2026.2713043","DOIUrl":"10.1080/13543784.2026.2713043","url":null,"abstract":"Introduction: Obesity is a chronic metabolic disease associated with insulin resistance, cardiometabolic complications, and increased mortality. Limitations of existing therapies have driven interests in alternative biological targets, including the endocannabinoid system and the cannabinoid-1 receptor (CB1R) signaling pathway.Areas covered: This review examines the rationale for targeting peripheral CB1R signaling and summarizes preclinical and clinical evidence supporting peripherally restricted CB1R antagonists and inverse agonists for obesity and related metabolic disorders. The metabolic effects of CB1R blockade in peripheral tissues are discussed, as well as distinctions between central and peripheral CB1R inhibition. The article also reviews the current development landscape of CB1R-targeted compounds, including agents evaluated in early-phase clinical trials. Literature was identified through PubMed, Embase, and Scopus, supplemented by ClinicalTrials.gov.Expert opinion: Peripherally restricted CB1R antagonists aim to deliver the metabolic benefits of CB1R blockade while avoiding the toxicity that ended development of centrally acting agents such as rimonabant. Recent phase 2 data with monlunabant demonstrated dose-dependent psychiatric adverse events and high discontinuation rates. Nimacimab, an antibody-based approach, has shown only marginal efficacy. The future of this drug class will therefore likely depend on rigorous long-term safety evaluation, biased CB1R pharmacology, and multitarget strategies including combinations with incretin-based therapies.","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"555-564"},"PeriodicalIF":4.3,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148790153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lonvoguran ziclumeran: a CRISPR-CAS9-based gene therapy for the treatment of hereditary angioedema. LONVOGURAN ZICLUMERAN：一种基于crispr - cas9的基因疗法治疗遗传性血管性水肿。

IF 4.3 2区医学

Expert opinion on investigational drugs Pub Date : 2026-07-01 Epub Date: 2026-07-29 DOI: 10.1080/13543784.2026.2710107

Long Hoang Luong, Shane Stone, Van Bui, Bharosha Bhattarai, Mai Thi Vu, E Pelinsu Aydin, Timothy Craig

{"title":"Lonvoguran ziclumeran: a CRISPR-CAS9-based gene therapy for the treatment of hereditary angioedema.","authors":"Long Hoang Luong, Shane Stone, Van Bui, Bharosha Bhattarai, Mai Thi Vu, E Pelinsu Aydin, Timothy Craig","doi":"10.1080/13543784.2026.2710107","DOIUrl":"10.1080/13543784.2026.2710107","url":null,"abstract":"Introduction: Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent swelling caused by dysregulation of the kallikrein-kinin pathway. Although current therapies effectively reduce attack frequency, treatment remains lifelong. Lonvoguran ziclumeran (Lonvo-z; NTLA-2002) is the first systemically administered in vivo CRISPR/Cas9 gene-editing therapy designed to provide durable suppression of plasma kallikrein through permanent disruption of the KLKB1 gene.Areas covered: This review summarizes the pathophysiology and current management of HAE, the development of Lonvo-z, its lipid nanoparticle delivery platform, and the technical advances enabling in vivo genome editing. Preclinical studies and clinical evidence, including early-phase trials and the Phase 3 HAELO study, are reviewed with emphasis on efficacy, safety and clinical implications.Expert opinion: Lonvo-z represents a major milestone in precision medicine and the clinical application of systemic genome editing. A single administration has produced sustained reductions in plasma kallikrein levels and HAE attack frequency. Although long-term follow-up is ongoing, current evidence supports its potential as the first one-time disease-modifying treatment for HAE and a landmark advance in CRISPR-based therapeutics.","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"545-553"},"PeriodicalIF":4.3,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148591122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Budigalimab: a viable option for patients with advanced solid tumors. 布地利布：晚期实体瘤患者的可行选择。

IF 4.3 2区医学

Expert opinion on investigational drugs Pub Date : 2026-07-01 Epub Date: 2026-08-03 DOI: 10.1080/13543784.2026.2710113

Alice Mogenet, Laurent Greillier

{"title":"Budigalimab: a viable option for patients with advanced solid tumors.","authors":"Alice Mogenet, Laurent Greillier","doi":"10.1080/13543784.2026.2710113","DOIUrl":"10.1080/13543784.2026.2710113","url":null,"abstract":"Introduction: Immune checkpoint inhibitors transformed lung cancer treatment and prognosis, new drugs are currently being developed to continue to improve patient's outcome and especially surrogate immune checkpoint for each pharma company pipeline.Areas covered: We conducted a literature review on Budigalimab to describe current data on drug pharmacokinetics and pharmacodynamics alongside clinical efficacy and safety outcomes. Budigalimab is a newly developed monoclonal antibody targeting programmed cell death 1 (PD1), enhanced with an Fc mutation to limit effector function in contrast to comparable drugs on the market. Phase I data successfully highlighted safety and expected efficacy as a single agent with flat dosage (250 mg Q2W, 375 Q3W, or 500 mg Q4W) across various tumor types. Drug development is now focusing on combination strategies given the massive number of drugs in the pipeline. Phase II and phase III data are still pending but promising trials are currently running across various tumor types.Expert opinion: Budigalimab is a new PD1 targeted immune checkpoint that is likely to be developed in association with other anticancer drugs within the Abbvie pipeline.","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"539-544"},"PeriodicalIF":4.3,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148663616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Consideration of the use of nalbuphine in idiopathic pulmonary fibrosis-associated cough: to cough or not to cough so much? 考虑使用纳布啡治疗特发性肺纤维化相关性咳嗽：咳还是不咳那么多？

IF 4.3 2区医学

Expert opinion on investigational drugs Pub Date : 2026-07-01 Epub Date: 2026-07-05 DOI: 10.1080/13543784.2026.2698522

Sheila A Doggrell

{"title":"Consideration of the use of nalbuphine in idiopathic pulmonary fibrosis-associated cough: to cough or not to cough so much?","authors":"Sheila A Doggrell","doi":"10.1080/13543784.2026.2698522","DOIUrl":"10.1080/13543784.2026.2698522","url":null,"abstract":"Cough is very common in idiopathic pulmonary fibrosis (IPF) and reduces quality of life. A low dose of the opioid µ-receptor agonist morphine reduced cough in subjects with IPF in a phase 2 clinical trial. However, the use of morphine for cough may be limited by adverse events (e.g. constipation) and its addiction potential. As a µ-receptor antagonist/partial agonist and κ-receptor agonist, nalbuphine may have less adverse events and be more effective against cough than morphine. In a phase 2b study (CORAL), after 6 weeks, nalbuphine 54 and 108 mg twice daily orally reduced the frequency of cough (by up to 60%), the severity of cough and improved the quality of life in subjects with IPF. Notably, the cough rate remained relatively high with nalbuphine and adverse events were common. Future studies should be directed at doses of nalbuphine or morphine that could possibly cause a greater or similar reduction in cough with a lesser incidence of adverse events. Although, the opioid agonists tested so far are not ideal treatments for cough in IPF, they are probably the best agents available to date. Nevertheless, the search for other agents with improved profiles between benefit and adverse events should continue.","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"499-502"},"PeriodicalIF":4.3,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148375076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Elezanumab for the treatment of spinal cord injury: assessing the clinical development journey to date. Elezanumab用于治疗脊髓损伤：评估迄今为止的临床发展历程。

IF 4.3 2区医学

Expert opinion on investigational drugs Pub Date : 2026-07-01 Epub Date: 2026-07-09 DOI: 10.1080/13543784.2026.2698524

Andrea J Mothe, Philippe P Monnier, Charles H Tator, Michael G Fehlings

{"title":"Elezanumab for the treatment of spinal cord injury: assessing the clinical development journey to date.","authors":"Andrea J Mothe, Philippe P Monnier, Charles H Tator, Michael G Fehlings","doi":"10.1080/13543784.2026.2698524","DOIUrl":"10.1080/13543784.2026.2698524","url":null,"abstract":"Introduction: Traumatic spinal cord injury (SCI) is a debilitating condition with serious neurological and quality of life impact. Despite advances in surgical, medical and rehabilitative care, no approved therapies currently promote neural repair or regeneration. Repulsive Guidance Molecule a (RGMa) is a potent inhibitor of neurite growth that also regulates neuronal survival and differentiation during development. In the adult central nervous system (CNS), RGMa is expressed at low levels and rapidly upregulated in multiple cell types following SCI. RGMa-neogenin signaling induces growth cone collapse, inhibits axonal regeneration, and contributes to neuronal death and neuroinflammation, limiting recovery. Human monoclonal antibodies targeting RGMa, including elezanumab, have shown neuroprotective and neuroregenerative effects in preclinical models, supporting clinical investigation.Areas covered: This review outlines SCI pathophysiology, RGMa upregulation after injury, key CNS signaling mechanisms, and the early development of anti-RGMa monoclonal antibodies.Expert opinion: Two concurrent, independent clinical trials of anti-RGMa antibodies offer a unique opportunity for cross-validation and comparison across patient populations. However, these trials were recently completed, and results are not yet reported. The translation of SCI therapeutics to clinical practice is historically challenging and the controlled conditions of preclinical studies may not fully capture the complexity and variability of human SCI.","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"519-531"},"PeriodicalIF":4.3,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148404174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

SOT201: cis-acting PD-1/IL-15 mutein-based immunocytokine under investigational study in solid tumors. SOT201：基于顺式作用PD-1/IL-15蛋白的免疫细胞因子在实体瘤中的研究

IF 4.3 2区医学

Expert opinion on investigational drugs Pub Date : 2026-06-01 Epub Date: 2026-06-03 DOI: 10.1080/13543784.2026.2683841

Vladyslav Mazhara, Irfan Baki Kilic, Irena Adkins, Radek Spisek, Marek Kovar

{"title":"SOT201: cis-acting PD-1/IL-15 mutein-based immunocytokine under investigational study in solid tumors.","authors":"Vladyslav Mazhara, Irfan Baki Kilic, Irena Adkins, Radek Spisek, Marek Kovar","doi":"10.1080/13543784.2026.2683841","DOIUrl":"10.1080/13543784.2026.2683841","url":null,"abstract":"Introduction: The systemic administration of cytokines is constrained by their pleiotropic activity, dose-dependent toxicities, and short serum half-life, limiting their therapeutic window in cancer treatment. To overcome these challenges, strategies that restrict cytokine signaling to defined immune cell subsets within the tumor microenvironment have been developed to enhance efficacy while minimizing off-target effects. Among these, antibody-cytokine fusion proteins represent a rational design platform that enables selective and localized cytokine delivery to specific immune populations.Areas covered: This report outlines the design principles underlying tumor-associated antigen-targeted and cis-delivered IL-2- and IL-15-based immunocytokine platforms, with particular emphasis on the PD-1-directed cis-signaling strategy. Preclinical data on SOT201 are summarized, highlighting how its affinity optimized IL-15 mutein promote selective proliferation and enhanced effector function of PD-1+ CD8+ T cells.Expert opinion: Cis-acting immunocytokines represent a promising class of advanced therapeutics that selectively direct cytokine payload to tumor infiltrating lymphocytes. This strategy has been shown to induce durable antitumor immunity and, in some cases, promote immune memory formation while limiting systemic toxicity. Ongoing clinical evaluation and rational combination approaches will ultimately define its therapeutic positioning in precision cancer immunotherapy.","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"393-400"},"PeriodicalIF":4.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148137099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0